+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.

Age: 18Years +All GendersPhase 2
221 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
P

Actively Recruiting

Heart disease is a leading cause of death across diverse groups in the United States. Researchers are evaluating whether screening for early heart artery plaque and early treatment can help manage mild heart disease. This study focuses on adults with low 10-year heart disease risk but who have risk factors and early signs of plaque buildup in their heart arteries. The trial has two phases screening and treatment. Screening uses special CT scans to detect calcium or plaque in heart arteries. In the treatment phase, about 1,500 participants with specific plaque findings are randomly assigned to take either rosuvastatin, colchicine, both medications, or placebos daily for two years. All participants receive guidance on heart-healthy lifestyle changes. Study drugs are mailed to participants homes, and visits include mostly virtual check-ins and a few in-person imaging appointments. Participants will attend up to two in-person screening visits and several phone visits during treatment, with imaging scans at the start and end of the trial. Blood samples are collected at home using mailed kits at multiple time points. Researchers will measure changes in plaque volume in heart arteries using advanced scans at two years, along with medication adherence and safety. The total study duration for participants is approximately two years.

Age: 30Years - 60YearsAll GendersPhase 3
23 locations